Jun 08, 2023 / 08:00PM GMT
Unidentified Participant
Hello, everyone, and welcome to the 2023 Jefferies Healthcare Conference. With me today is Hans Schambye from Galecto.
Hans Schambye - Galecto, Inc. - CEO
Thanks a lot. And thank you for coming for this presentation. So I'm going to talk to you about Galecto and I will be making forward-looking statements. You can see this on our website.
So Galecto is a really exciting company that's working on changing the lives of patients with fibrosis. And we include cancers in that because we believe we have transformative drugs that can really impact the center of the cause of these diseases.
So we are in the unique situation that we have three different compounds in clinical testing. And we already have positive clinical data from each of these three compounds. We are also well capitalized. We had $57 million at the end of last quarter which covers us right through to the end of second half of next year, including all of the activities that I'll be talking about.
We are developing small molecule therapeutics targeting two
Galecto Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers